Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review

Christos Damaskos; Nikolaos Garmpis; Dimitrios Dimitroulis; Anna Garmpi; Iason Psilopatis; Panagiotis Sarantis; Evangelos Koustas; Prodromos Kanavidis; Dionysios Prevezanos; Gregory Kouraklis; Michail V. Karamouzis; Georgios Marinos; Konstantinos Kontzoglou; Efstathios A. Antoniou

doi:10.3390/ijms232214117

International Journal of Molecular Sciences (Nov 2022)

Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review

Christos Damaskos,
Nikolaos Garmpis,
Dimitrios Dimitroulis,
Anna Garmpi,
Iason Psilopatis,
Panagiotis Sarantis,
Evangelos Koustas,
Prodromos Kanavidis,
Dionysios Prevezanos,
Gregory Kouraklis,
Michail V. Karamouzis,
Georgios Marinos,
Konstantinos Kontzoglou,
Efstathios A. Antoniou

Affiliations

Christos Damaskos: Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece
Nikolaos Garmpis: Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Dimitrios Dimitroulis: Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Anna Garmpi: First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Iason Psilopatis: Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt—Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Panagiotis Sarantis: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Evangelos Koustas: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Prodromos Kanavidis: Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Dionysios Prevezanos: Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece
Gregory Kouraklis: Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Michail V. Karamouzis: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Georgios Marinos: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Konstantinos Kontzoglou: Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Efstathios A. Antoniou: Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

DOI: https://doi.org/10.3390/ijms232214117
Journal volume & issue: Vol. 23, no. 22
p. 14117

Abstract

Read online

Hepatocellular carcinoma (HCC) remains one of the most common malignancies and the third cause of cancer-related death worldwide, with surgery being the best prognostic tool. Among the well-known causative factors of HCC are chronic liver virus infections, chronic virus hepatitis B (HBV) and chronic hepatitis virus C (HCV), aflatoxins, tobacco consumption, and non-alcoholic liver disease (NAFLD). There is a need for the development of efficient molecular markers and alternative therapeutic targets of great significance. In this review, we describe the general characteristics of HCC and present a variety of targeted therapies that resulted in progress in HCC therapy.

Published in International Journal of Molecular Sciences

ISSN: 1661-6596 (Print); 1422-0067 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General); Science: Chemistry
Website: http://www.mdpi.com/journal/ijms

About the journal

Abstract

Keywords